Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (211-220 of 251) with videos related to

Pageof 26
Sort By:
Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Iscience|April 3, 2023
Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activationJeoffrey Pelletier, Marielle Balzano, Jérôme Destin, et al.
Blood Advances|July 2, 2024
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AMLJulien M P Grenier, Céline Testut, Matthieu Bal, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcomeAnne-Sophie Chretien, Raynier Devillier, Samuel Granjeaud, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood|April 30, 2011
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemiaMélanie Bonnet, Marie Loosveld, Bertrand Montpellier, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Pageof 26

Showing results (211-220 of 251) with videos related to

Sort By:
Pageof 26
Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Iscience|April 3, 2023
Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activationJeoffrey Pelletier, Marielle Balzano, Jérôme Destin, et al.
Blood Advances|July 2, 2024
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AMLJulien M P Grenier, Céline Testut, Matthieu Bal, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2021
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcomeAnne-Sophie Chretien, Raynier Devillier, Samuel Granjeaud, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood|April 30, 2011
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemiaMélanie Bonnet, Marie Loosveld, Bertrand Montpellier, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Pageof 26